Novo Nordisk B

Wegovy HD’s FDA approval boosts Novo Nordisk’s obesity lineup, delivering up to 20.7 % weight loss and positioning it to rival Lilly’s Mounjaro in the U.S. market.

New Nordisk’s stock jumps 10 % as FDA approves Wegovy tablet, opening a new U.S. revenue stream and boosting investor optimism.

Novo Nordisk’s first oral GLP‑1 weight‑management pill, Wegovy® pill, hits FDA and EMA approvals, expands to India, and could shift its stock outlook.

Novo Nordisk B, a leading Danish pharmaceutical company, is undergoing a major governance overhaul after a prolonged dispute with its primary shareholder, the Novo Nordisk Foundation, over the future composition and strategic direction of the board.

Novo Nordisk’s stock price plummeted 6.4% after former US President Donald Trump announced a plan to reduce tariffs on fertility treatments and the medication Ozempic, potentially undermining the company’s pricing power in the US market.